Aditxt Plummets 38.66%: Merger Collapse and Sector Turbulence Ignite Sell-Off

Summary
• Aditxt (ADTX) crashes to $0.119, down 38.66% from $0.194
• Intraday range spans $0.0901 to $0.1711 amid 3,760% surge in turnover
• Evofem terminates $1.45B merger, triggering sector-wide uncertainty

Aditxt’s stock has imploded on October 28, 2025, as the termination of its merger with Evofem Biosciences sent shockwaves through the biotech sector. With a 52-week high of $135.5 and a current price near its 52-week low, the stock’s collapse reflects a perfect storm of regulatory setbacks, capital flight, and strategic missteps. The day’s $0.119 close—a 38.66% drop—underscores the fragility of speculative biotech valuations in a tightening capital environment.

Merger Collapse and Capital Flight Fuel ADTX’s Freefall
The abrupt termination of Aditxt’s merger with Evofem Biosciences—announced on October 20, 2025—has become the catalyst for ADTX’s catastrophic decline. Shareholders rejected the Amended and Restated Merger Agreement, forcing Evofem to terminate the deal and refocus on standalone growth. This decision shattered investor confidence in Aditxt’s strategic value, particularly as the company’s pipeline of diagnostics and therapeutics (e.g., Mitomic™ Endometriosis Test, ADI-100™) remains unproven. Compounding the issue, Evofem’s pivot to target 2027 EBITDA positivity and a national listing has shifted capital away from ADTX, leaving the stock vulnerable to margin calls and short-covering pressure.

Technical Deterioration and ETF Correlation Signal Short-Term Dangers
• 200-day average: $1.4544 (far above current price)
• RSI: 13.69 (oversold territory)
• MACD: -0.176 (bearish divergence)
• Bollinger Bands: Price at $0.112956 (lower band), indicating extreme volatility

ADTX’s technical profile is a textbook bear trap. The stock is trading below all major moving averages, with RSI at a 14-day low and MACD signaling accelerating bearish momentum. Short-term traders should monitor the $0.0901 intraday low as a critical support level; a break below this could trigger a 50%+ drop to $0.05. The absence of leveraged ETFs and options liquidity means position sizing must be conservative. Given the lack of options data, focus on ETFs like XLB (Biotech Select Sector SPDR) for sector exposure, though XLB’s -1.92% intraday decline suggests broader risk aversion.

Backtest Aditxt Stock Performance
Below is an interactive event-study report that evaluates how Aditxt (ADTX.O) behaved after every intraday plunge of ≥ 39 % from 2022-01-03 through 2025-10-28. You can scroll the table or switch tabs to inspect win-rate curves, cumulative abnormal returns, and other statistics.Key takeaways (30-day holding horizon):• Only 6 such extreme plunges occurred; the post-event performance is overwhelmingly negative. • Average cumulative return after 30 days: –61.96 % vs –31.44 % for the stock’s own baseline, with statistical significance from day 16 onward. • Win-rate never exceeds 33 % beyond the 2-day mark and drops to 0 % after day 15.These results suggest that buying the dip after a –39 % intraday shock has historically not been rewarded for ADTX.

ADTX’s Freefall: Prepare for a $0.05 Bottom or Regulatory Rebound?
Aditxt’s collapse is far from over. With the merger terminated, capital flight accelerating, and technical indicators in freefall, the stock faces a high probability of testing its 52-week low of $0.0901—potentially falling to $0.05 if short-sellers dominate. Investors should watch for a breakdown below $0.0901 or a surprise catalyst (e.g., FDA approval of Mitomic™ diagnostics). Meanwhile, sector leader Illumina (ILMN) fell 1.92%, signaling broader biotech fragility. For now, the message is clear: ADTX is a high-risk, high-reward trade—only for those with deep pockets and a stomach for volatility.